ACESO

Aceso Biopharma is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule drugs and targeted protein degraders for oncology and immunological disorders. Headquartered in Suzhou, China, the company utilizes its proprietary drug discovery platform to create high-potency therapeutics, including PROTAC (Proteolysis-Targeting Chimera) molecules. Its lead clinical candidate, AC003, is a selective FLT3 inhibitor being evaluated for the treatment of acute myeloid leukemia. Additionally, the company is advancing AC0682, an oral ER degrader, and AC0176, a BTK inhibitor, through early-stage clinical trials. Aceso Biopharma aims to provide precision medicine solutions for patients with limited treatment options in the cancer and autoimmune space.